BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29656518)

  • 1. Genotype-specific progression of hereditary medullary thyroid cancer.
    Machens A; Lorenz K; Weber F; Dralle H
    Hum Mutat; 2018 Jun; 39(6):860-869. PubMed ID: 29656518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymph node metastasis in hereditary medullary thyroid cancer is independent of the underlying RET germline mutation.
    Machens A; Lorenz K; Weber F; Dralle H
    Eur J Surg Oncol; 2021 Apr; 47(4):920-923. PubMed ID: 32962888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rare RET Variant p.D707E in a Chinese Pedigree with Hereditary Medullary Thyroid Carcinoma.
    Zhang L; Li X; Li Q; Ge S; Chen M; Huang S; Chen B; Li P; Teng B; Xu J; Zhao S; Qi F; Zhang Y
    Pathobiology; 2017; 84(3):152-160. PubMed ID: 27798940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening of RET gene mutations in Chinese patients with medullary thyroid carcinoma and their relatives.
    Wang J; Zhang B; Liu W; Zhang Y; Di X; Yang Y; Yan D
    Fam Cancer; 2016 Jan; 15(1):99-104. PubMed ID: 26254625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. All in the family? Analyzing the impact of family history in addition to genotype on medullary thyroid carcinoma aggressiveness in MEN2A patients.
    Long KL; Etzel C; Rich T; Hyde S; Perrier ND; Graham PH; Lee JE; Hu MI; Cote GJ; Gagel R; Grubbs EG
    Fam Cancer; 2017 Apr; 16(2):283-289. PubMed ID: 27864651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. M918V RET mutation causes familial medullary thyroid carcinoma: study of 8 affected kindreds.
    Martins-Costa MC; Cunha LL; Lindsey SC; Camacho CP; Dotto RP; Furuzawa GK; Sousa MS; Kasamatsu TS; Kunii IS; Martins MM; Machado AL; Martins JR; Dias-da-Silva MR; Maciel RM
    Endocr Relat Cancer; 2016 Dec; 23(12):909-920. PubMed ID: 27807060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey.
    Aydoğan Bİ; Yüksel B; Tuna MM; Navdar Başaran M; Akkurt Kocaeli A; Ertörer ME; Aydın K; Güldiken S; Şimşek Y; Cihan Karaca Z; Yılmaz M; Aktürk M; Anaforoğlu İ; Kebapçı N; Duran C; Taşlıpınar A; Kulaksızoğlu M; Gürsoy A; Dağdelen S; Erdoğan MF
    J Clin Res Pediatr Endocrinol; 2016 Mar; 8(1):13-20. PubMed ID: 26758973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotypic characteristics and their association with phenotypic characteristics of hereditary medullary thyroid carcinoma in Korea.
    Jung KY; Kim SM; Kim MJ; Cho SW; Kim BW; Lee YS; Jeong JJ; Nam KH; Chung WY; Lee KE; Chung EJ; Kim HJ; Park DJ; Sung MW; Park CS; Cho BY; Park YJ; Chang HS
    Surgery; 2018 Aug; 164(2):312-318. PubMed ID: 29779869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression.
    Smith J; Read ML; Hoffman J; Brown R; Bradshaw B; Campbell C; Cole T; Navas JD; Eatock F; Gundara JS; Lian E; Mcmullan D; Morgan NV; Mulligan L; Morrison PJ; Robledo M; Simpson MA; Smith VE; Stewart S; Trembath RC; Sidhu S; Togneri FS; Wake NC; Wallis Y; Watkinson JC; Maher ER; McCabe CJ; Woodward ER
    Hum Mol Genet; 2016 May; 25(9):1836-45. PubMed ID: 26945007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early, Prophylactic Thyroidectomy in Hereditary Medullary Thyroid Carcinoma: A 26-year Monoinstitutional Experience.
    Pelizzo MR; Torresan F; Boschin IM; Nacamulli D; Pennelli G; Barollo S; Rubello D; Mian C
    Am J Clin Oncol; 2015 Oct; 38(5):508-13. PubMed ID: 24064755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chinese siblings with hereditary medullary thyroid carcinoma caused by RET mutation: implications for RET oncogene detection.
    Huang Q; Hu A; Zhang M
    BMC Endocr Disord; 2020 May; 20(1):64. PubMed ID: 32408902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma.
    Opsahl EM; Brauckhoff M; Schlichting E; Helset K; Svartberg J; Brauckhoff K; Mæhle L; Engebretsen LF; Sigstad E; Grøholt KK; Akslen LA; Jørgensen LH; Varhaug JE; Bjøro T
    Thyroid; 2016 Sep; 26(9):1225-38. PubMed ID: 27400880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline RET mutation carriers in Japanese patients with apparently sporadic medullary thyroid carcinoma: A single institution experience.
    Kihara M; Miyauchi A; Yoshioka K; Oda H; Nakayama A; Sasai H; Yabuta T; Masuoka H; Higashiyama T; Fukushima M; Ito Y; Kobayashi K; Miya A
    Auris Nasus Larynx; 2016 Oct; 43(5):551-5. PubMed ID: 26837867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RET codon 609 mutations: a contribution for better clinical managing.
    Mian C; Sartorato P; Barollo S; Zane M; Opocher G
    Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):33-6. PubMed ID: 22584703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple endocrine neoplasia 2 in Cyprus: evidence for a founder effect.
    Fanis P; Skordis N; Frangos S; Christopoulos G; Spanou-Aristidou E; Andreou E; Manoli P; Mavrommatis M; Nicolaou S; Kleanthous M; Cariolou MA; Christophidou-Anastasiadou V; Tanteles GA; Phylactou LA; Neocleous V
    J Endocrinol Invest; 2018 Oct; 41(10):1149-1157. PubMed ID: 29396759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma.
    D'Aloiso L; Carlomagno F; Bisceglia M; Anaganti S; Ferretti E; Verrienti A; Arturi F; Scarpelli D; Russo D; Santoro M; Filetti S
    J Clin Endocrinol Metab; 2006 Mar; 91(3):754-9. PubMed ID: 16384843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
    Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
    Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations.
    Barletta JA; Nosé V; Sadow PM
    Endocr Pathol; 2021 Mar; 32(1):35-43. PubMed ID: 33492588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RET germline mutations identified by exome sequencing in a Chinese multiple endocrine neoplasia type 2A/familial medullary thyroid carcinoma family.
    Qi XP; Ma JM; Du ZF; Ying RB; Fei J; Jin HY; Han JS; Wang JQ; Chen XL; Chen CY; Liu WT; Lu JJ; Zhang JG; Zhang XN
    PLoS One; 2011; 6(5):e20353. PubMed ID: 21655256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.